PLAINSBORO, N.J., June 26, 2021 /PRNewswire/ -- Novo Nordisk today presented data showing that an investigational 2 mg dose of Ozempic® (semaglutide) injection provided statistically significant and superior reductions in blood sugar (A1C) compared with Ozempic® 1 mg.1 These data were the...
from PR Newswire: https://ift.tt/35TXgN5
No comments:
Post a Comment